In this regard, histamine is being administered as an adjuvant to immunotherapy with IL-2 for the treatment of patients with metastatic melanoma and acute myeloid leukaemia, demonstrating clinical benefits.24,52. The gene discussed is IL2; the disease is metastatic melanoma.